Literature DB >> 19604447

Is the clinical picture of Schnitzler syndrome always Schnitzler syndrome?

A Markotić1, V Skerk, L Cvetko Krajinović, A Beus.   

Abstract

Here we present two cases, a female and a male patient with Schnitzler-like syndrome. Both patients had two major (monoclonal gammopathy and chronic urticaria) and almost all minor symptoms (e.g. arthralgia, bone pain, fever, etc.) of Schnitzler syndrome. It is considered that interleukine (IL)-1 has important influence on immunopathogenesis of Schnitzler syndrome. However, when looked at the immune response in our two patients, we found significant differences between them. In the sera of the female patient, IL-1beta was increased. However, the highest increase was found for granulocyte- colony stimulating factor (G-CSF), IL-32 alpha and IL-17E (IL-25). The male patient had a significant increase in the percentage of NK-cells, a decrease in CD4+ helper cells and no increase in cytokine levels. In both patients an increase in CD40L (CD154) was found. Our statement is that, besides clinical symptoms and signs, additional immune parameters should be tested before diagnosis of Schnitzler syndrome is established.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19604447

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

1.  Different Therapeutic Paths (Colchicine vs. Anakinra) in Two Patients With Schnitzler's Syndrome.

Authors:  Marko Barešić; Joško Mitrović; Jadranka Morović Vergles; Branimir Anić
Journal:  Arch Rheumatol       Date:  2016-07-11       Impact factor: 1.472

Review 2.  Schnitzler's syndrome: lessons from 281 cases.

Authors:  Heleen D de Koning
Journal:  Clin Transl Allergy       Date:  2014-12-05       Impact factor: 5.871

Review 3.  Natural Killer Cells in Systemic Autoinflammatory Diseases: A Focus on Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome.

Authors:  Jessica Vandenhaute; Carine H Wouters; Patrick Matthys
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.